Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cerebral Diseases

Paolo Gelosa, Francesca Colazzo, Elena Tremoli, Luigi Sironi, Laura Castiglioni

Research output: Contribution to journalReview articlepeer-review


Cysteinyl leukotrienes (CysLTs) are potent lipid mediators widely known for their actions in asthma and in allergic rhinitis. Accumulating data highlights their involvement in a broader range of inflammation-associated diseases such as cancer, atopic dermatitis, rheumatoid arthritis, and cardiovascular diseases. The reported elevated levels of CysLTs in acute and chronic brain lesions, the association between the genetic polymorphisms in the LTs biosynthesis pathways and the risk of cerebral pathological events, and the evidence from animal models link also CysLTs and brain diseases. This review will give an overview of how far research has gone into the evaluation of the role of CysLTs in the most prevalent neurodegenerative disorders (ischemia, Alzheimer's and Parkinson's diseases, multiple sclerosis/experimental autoimmune encephalomyelitis, and epilepsy) in order to understand the underlying mechanism by which they might be central in the disease progression.

Original languageEnglish
Article number3454212
JournalMediators of Inflammation
Publication statusPublished - Jan 1 2017

ASJC Scopus subject areas

  • Immunology
  • Cell Biology


Dive into the research topics of 'Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cerebral Diseases'. Together they form a unique fingerprint.

Cite this